These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 25484108)

  • 1. Effect of recent spinal cord injury on wnt signaling antagonists (sclerostin and dkk-1) and their relationship with bone loss. A 12-month prospective study.
    Gifre L; Vidal J; Carrasco JL; Filella X; Ruiz-Gaspà S; Muxi A; Portell E; Monegal A; Guañabens N; Peris P
    J Bone Miner Res; 2015 Jun; 30(6):1014-21. PubMed ID: 25484108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover.
    Gifre L; Ruiz-Gaspà S; Monegal A; Nomdedeu B; Filella X; Guañabens N; Peris P
    Bone; 2013 Nov; 57(1):272-6. PubMed ID: 23981659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors associated with serum soluble inhibitors of Wnt-β-catenin signaling (sclerostin and dickkopf-1) in patients undergoing peritoneal dialysis.
    Yamada S; Tsuruya K; Tokumoto M; Yoshida H; Ooboshi H; Kitazono T
    Nephrology (Carlton); 2015 Sep; 20(9):639-45. PubMed ID: 25974190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of recent spinal cord injury on the OPG/RANKL system and its relationship with bone loss and the response to denosumab therapy.
    Gifre L; Ruiz-Gaspà S; Carrasco JL; Portell E; Vidal J; Muxi A; Monegal A; Guañabens N; Peris P
    Osteoporos Int; 2017 Sep; 28(9):2707-2715. PubMed ID: 28580511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density.
    Voskaridou E; Christoulas D; Plata E; Bratengeier C; Anastasilakis AD; Komninaka V; Kaliontzi D; Gkotzamanidou M; Polyzos SA; Dimopoulou M; Terpos E
    Horm Metab Res; 2012 Nov; 44(12):909-13. PubMed ID: 22581647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for the development of osteoporosis after spinal cord injury. A 12-month follow-up study.
    Gifre L; Vidal J; Carrasco JL; Muxi A; Portell E; Monegal A; Guañabens N; Peris P
    Osteoporos Int; 2015 Sep; 26(9):2273-80. PubMed ID: 25939310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Denosumab increases sublesional bone mass in osteoporotic individuals with recent spinal cord injury.
    Gifre L; Vidal J; Carrasco JL; Muxi A; Portell E; Monegal A; Guañabens N; Peris P
    Osteoporos Int; 2016 Jan; 27(1):405-10. PubMed ID: 26423406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of aromatase inhibition on serum levels of sclerostin and dickkopf-1, bone turnover markers and bone mineral density in women with breast cancer.
    Kyvernitakis I; Rachner TD; Urbschat A; Hars O; Hofbauer LC; Hadji P
    J Cancer Res Clin Oncol; 2014 Oct; 140(10):1671-80. PubMed ID: 24903965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sclerostin levels and changes in bone metabolism after bariatric surgery.
    Muschitz C; Kocijan R; Marterer C; Nia AR; Muschitz GK; Resch H; Pietschmann P
    J Clin Endocrinol Metab; 2015 Mar; 100(3):891-901. PubMed ID: 25490275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial.
    Anastasilakis AD; Polyzos SA; Gkiomisi A; Bisbinas I; Gerou S; Makras P
    J Clin Endocrinol Metab; 2013 Aug; 98(8):3206-12. PubMed ID: 23788684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating Wnt/β-catenin signalling inhibitors and uraemic vascular calcifications.
    Yang CY; Chang ZF; Chau YP; Chen A; Yang WC; Yang AH; Lee OK
    Nephrol Dial Transplant; 2015 Aug; 30(8):1356-63. PubMed ID: 25817223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucocorticoid therapy causes contradictory changes of serum Wnt signaling-related molecules in systemic autoimmune diseases.
    Kawazoe M; Kaneko K; Shikano K; Kusunoki N; Nanki T; Kawai S
    Clin Rheumatol; 2018 Aug; 37(8):2169-2178. PubMed ID: 28551822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant tamoxifen but not aromatase inhibitor therapy decreases serum levels of the Wnt inhibitor dickkopf-1 while not affecting sclerostin in breast cancer patients.
    Göbel A; Kuhlmann JD; Link T; Wimberger P; Browne AJ; Rauner M; Hofbauer LC; Rachner TD
    Breast Cancer Res Treat; 2017 Aug; 164(3):737-743. PubMed ID: 28526959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationship between inhibitors of the Wnt signalling pathway (Dickkopf-1(DKK1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in post-menopausal women.
    Hampson G; Edwards S; Conroy S; Blake GM; Fogelman I; Frost ML
    Bone; 2013 Sep; 56(1):42-7. PubMed ID: 23702386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of strontium ranelate on bone mass and bone turnover in women with thalassemia major-related osteoporosis.
    Morabito N; Catalano A; Gaudio A; Morini E; Bruno LM; Basile G; Tsiantouli E; Bellone F; Agostino RM; Piraino B; La Rosa MA; Salpietro C; Lasco A
    J Bone Miner Metab; 2016 Sep; 34(5):540-6. PubMed ID: 26204844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in Serum Levels of Myokines and Wnt-Antagonists after an Ultramarathon Race.
    Kerschan-Schindl K; Thalmann MM; Weiss E; Tsironi M; Föger-Samwald U; Meinhart J; Skenderi K; Pietschmann P
    PLoS One; 2015; 10(7):e0132478. PubMed ID: 26147574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating sclerostin and dickkopf-1 levels in ossification of the posterior longitudinal ligament of the spine.
    Kashii M; Matuso Y; Sugiura T; Fujimori T; Nagamoto Y; Makino T; Kaito T; Ebina K; Iwasaki M; Yoshikawa H
    J Bone Miner Metab; 2016 May; 34(3):315-24. PubMed ID: 26040409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in bone mineral density, markers of bone turnover and extracellular matrix and daily life muscular activity among patients with recent motor-incomplete versus motor-complete spinal cord injury.
    Kostovski E; Hjeltnes N; Eriksen EF; Kolset SO; Iversen PO
    Calcif Tissue Int; 2015 Feb; 96(2):145-54. PubMed ID: 25539858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wnt signaling pathway inhibitors, sclerostin and DKK-1, correlate with pain and bone pathology in patients with Gaucher disease.
    Ivanova MM; Dao J; Kasaci N; Friedman A; Noll L; Goker-Alpan O
    Front Endocrinol (Lausanne); 2022; 13():1029130. PubMed ID: 36506070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mice with sclerostin gene deletion are resistant to the severe sublesional bone loss induced by spinal cord injury.
    Qin W; Zhao W; Li X; Peng Y; Harlow LM; Li J; Qin Y; Pan J; Wu Y; Ran L; Ke HZ; Cardozo CP; Bauman WA
    Osteoporos Int; 2016 Dec; 27(12):3627-3636. PubMed ID: 27436301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.